YOLFTbeta
PlexBio Co., Ltd.

PlexBio Co., Ltd.

6572 · TWO · Healthcare / Medical Devices

6.28TWD+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close6.28
Open5.98
Day Range5.98 – 6.28
52-Week Range5.16 – 15.80
Volume20.32K
Market Cap721.40M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.37
Dividend Yield0.00%
Beta1.10
50-Day Avg7.39
200-Day Avg7.99

About

PlexBio Co., Ltd. develops and manufactures in vitro diagnostic reagents for molecular biology and immunology projects. It provides workflow navigation services; automated sample preparation kits; IntelliPlex platform that is designed for pCode technology with throughput sample-to-answer multiplexing assays; oncology assays, a portfolio for advanced molecular testing; and customized pCode assays. PlexBio Co., Ltd. was founded in 2009 and is based in Taipei, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEODr. Ting Cao Ph.D.
  • HeadquartersNo. 351, Yangguang Street, Taipei, Taiwan, 11491, Taiwan
  • Websitehttps://www.plexbio.com

Leadership

  • Dr. Ting Cao Ph.D.Chairman, President & CEO
  • Ms. Lipi YehChief Financial Officer
  • Jiahong HongAccounting Supervisor
  • Dr. Chin-Shiou HuangVP & CTO
  • Mr. Huei Te UweSenior Administration Manager
  • Dr. Jason LeiSenior Vice President of Research & Development

Financials

Income Statement

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-101.35M124.94M191.19M167.18M128.06M127.09M
Growth (%)--+23.28%+53.02%-12.56%-23.40%-0.76%
Cost of Revenue-59.67M86.38M132.19M104.71M78.80M86.68M
Gross Profit-41.68M38.56M58.99M62.47M49.26M40.41M
Gross Margin-41.13%30.86%30.86%37.37%38.46%31.80%
Operating Expense-189.99M173.82M125.93M126.62M128.79M106.06M
Operating Income--148.31M-135.26M-66.94M-64.15M-79.53M-65.65M
Operating Margin--146.34%-108.26%-35.01%-38.37%-62.10%-51.65%
EBITDA-148.63M-115.54M-106.81M-32.89M-40.28M-42.69M-45.71M
EBITDA Margin--114.00%-85.49%-17.20%-24.09%-33.34%-35.97%
Net Income--141.07M-131.59M-53.14M-58.53M-61.63M-62.47M
Net Income Margin--139.19%-105.32%-27.79%-35.01%-48.13%-49.15%
R&D-113.37M113.31M72.61M62.97M69.29M52.50M
R&D as % of Total Revenue-111.86%90.69%37.98%37.66%54.11%41.31%
Interest Expense386.00K234.00K226.00K167.00K263.00K164.00K265.00K
Interest Expense % of Total Revenue-0.23%0.18%0.09%0.16%0.13%0.21%

Balance Sheet

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets-823.23M732.80M582.15M516.66M572.38M446.59M
Total Liabilities-160.74M198.48M102.72M92.26M197.97M136.15M
Total Equity-662.49M534.32M479.43M424.40M374.41M310.44M
Cash-315.50M348.28M310.36M278.87M266.53M191.04M
Total Debt494.00K9.49M9.15M6.02M10.85M5.67M-
Net Debt494.00K-306.01M-339.13M-304.33M-268.02M-260.86M-

Cash Flow

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow--110.79M-84.33M-71.44M-29.27M-5.06M-79.10M
Investing Cash Flow--24.06M126.30M42.06M16.93M809.00K-
Financing Cash Flow-3.35M-8.91M-8.88M-18.99M-8.66M-
Capital Expenditure06.49M11.60M2.02M3.07M3.59M413.00K
Free Cash Flow--117.28M-95.94M-73.46M-32.31M-8.64M-79.52M
FCF to OCF-105.86%113.76%102.82%110.40%170.95%100.52%

Key Statistics & Ratios

Market Cap721.40M
Enterprise Value456.90M
Trailing P/E0.00
Forward P/E0.00
Price / Sales5.24
Price / Book2.54
EPS-0.37
Book Value2.79
Revenue (TTM)137.57M
Gross Profit (TTM)46.69M
EBITDA-48.22M
Profit Margin-27.90%
Operating Margin-35.10%
Return on Equity-12.45%
Return on Assets-7.45%
Shares Outstanding103.65M
Shares Float39.09M
Beta1.10
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%